Health Care [ 5/12 ] | Biotechnology [ 25/74 ]
NASDAQ | Common Stock
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States.
It offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair.
The company also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.
In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency.
The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; CellectisS. A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products.
Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 25, 25 | -2.14 Increased by +47.39% | -2.94 Increased by +27.47% |
| Nov 4, 24 | -2.25 Decreased by -3.11 K% | -1.92 Decreased by -17.19% |
| Aug 1, 24 | 4.67 Increased by +4.77 K% | -1.50 Increased by +411.33% |
| May 13, 24 | -0.35 Decreased by -52.17% | -1.91 Increased by +81.68% |
| Mar 27, 24 | -4.06 Decreased by -1.46 K% | -2.05 Decreased by -98.05% |
| Nov 7, 23 | -0.07 Increased by +68.18% | -0.16 Increased by +56.25% |
| Aug 4, 23 | -0.10 Increased by +78.26% | -0.24 Increased by +58.33% |
| May 9, 23 | -0.23 Increased by +50.00% | -0.23 |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 638.00 K Decreased by -90.93% | -17.75 M Decreased by -8.94% | Decreased by -2.78 K% Decreased by -1.10 K% |
| Sep 30, 24 | 576.00 K Decreased by -95.61% | -16.43 M Decreased by -103.30% | Decreased by -2.85 K% Decreased by -4.53 K% |
| Jun 30, 24 | 49.90 M Increased by +152.15% | 32.75 M Increased by +375.41% | Increased by +65.63% Increased by +209.22% |
| Mar 31, 24 | 17.58 M Increased by +100.27% | 8.59 M Increased by +136.45% | Increased by +48.84% Increased by +118.20% |
| Dec 31, 23 | 7.04 M Decreased by -33.59% | -16.29 M Increased by +55.36% | Decreased by -231.44% Increased by +32.77% |
| Sep 30, 23 | 13.12 M Increased by +78.19% | -8.08 M Increased by +67.63% | Decreased by -61.58% Increased by +81.84% |
| Jun 30, 23 | 19.79 M Increased by +418.04% | -11.89 M Increased by +63.38% | Decreased by -60.09% Increased by +92.93% |
| Mar 31, 23 | 8.78 M Increased by +164.70% | -23.56 M Increased by +18.74% | Decreased by -268.31% Increased by +69.30% |